📝 @fda.gov approvals in ccRCC and CCA, orphan drug and fast track designations in sarcoma, and a priority review in bladder cancer?

Test your knowledge with this week's news quiz: onclive.com/view/onclive...

#oncology #blcsm #kcsm #scmsm

Initial results from the phase 2 SURF302 trial showed the oral FGFR3-selective inhibitor dabogratinib generated responses in patients with FGFR3-altered low-grade, intermediate-risk NMIBC #blcsm #oncology

Read more: www.onclive.com/view/dabogra...